Abstract
Historically, in 1981, growth hormone-releasing peptides (GHRPs) initially were thought to reflect the actions of elusive GHRH but fortunately in 1982 GHRH was isolated. By 1984 GHRP-6 results revealed that the actions of GHRH and GHRP were distinguishable from each other. To appreciate GHRP and GHRH interrelationships on GH release, detailed in vitro and in vivo dose–response studies were essential. Over subsequent years GHRPs were studied by many talented basic and clinical investigators. By 1995 GHRP icv administration was found to increase food intake in conscious rats and in 1996 the GHS-1a receptor was cloned. Finally, in 1999 the GHRP/GHS natural hormone, ghrelin, was isolated, synthesized, and found to have essentially the same activity as that of GHRPs/GHSs in animals and humans. A major surprise and a reorienting finding was the primary anatomical location of ghrelin in the stomach and, in addition, strong enhancement of food intake. Over time, GH secretion has been hypothesized to be primarily regulated by the hypothalamic hypophysiotropic tripartite system of GHRH, ghrelin, and SRIF rather than the bipartite system of GHRH and SRIF. Since the isolation of ghrelin, actions of this hormone have continued to expand from the hypothalamic CNS to peripheral sites. This includes both direct and indirect actions particularly related to nutrition and metabolism as well as a cornucopia of unexpected actions. In summary, unnatural GHRP begot natural ghrelin and its receptor. This reverse pharmacology approach forecasts that variations of the unnatural to natural sequence of events likely will be more frequent, modified, expanded, and refined in the future.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bowers CY, Chang J, Momany F, et al. Effect of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: MacIntyre I, Szelke M, editors. Molecular endocrinology. Amsterdam: Elsevier/North-Holland Biomedical Press; 1977. p. 287–92.
Bowers CY, Momany F, Chang K, et al. Structure activity relationships of a synthetic pentapeptide that specifically releases GH in vitro. Endocrinology. 1980;106:663–7.
Bowers CY, Reynolds GA, Chang K, et al. A study on the regulation of GH release from the pituitaries of rats, in vitro. Endocrinology. 1981;108:1071–9.
Momany FA, Bowers CY, Reynolds GA, et al. Design, synthesis and biological activity of peptides which release growth hormone, in vitro. Endocrinology. 1981;108:31–9.
Momany F, Bowers CY, Reynolds GA, et al. Conformational energy studies and in vitro activity data on active GH releasing peptides. Endocrinology. 1984;114:1531–6.
Bowers CY, Momany F, Reynolds GA. In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. San Francisco, CA: The Endocrine Society. June 15–18, 1982. p. 205.
Bowers CY, Momany F, Reynolds GA, et al. On the In vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114:1537–45.
Bowers CY, Reynolds GA, Momany F. New advances on the regulation of growth hormone (GH) secretion. Int J Neurol. 1984;18:188–205.
Guillemin R, Brazeau P, Bohlen P, et al. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218:585–7.
Rivier J, Spiess J, Thorner M, et al. Characterization of a growth hormone releasing factor from a human pancreatic islet tumor. Nature. 1982;300:276–8.
Guillemin R. Growth hormone releasing factor: a brief history of its time. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 3–8.
Thorner MO, Perryman RL, Cronin A, et al. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone releasing factor. J Clin Invest. 1982;70:965–76.
Thorner MO, Spiess J, Vance ML, et al. Human pancreatic growth hormone-releasing factor selectively stimulated growth-hormone secretion in man. Lancet. 1983;1:24–8.
Frohman LA, Szabo M, Berelowitz M, et al. Partial purification and characterization of a peptide with growth hormone activity from extra-pituitary tumors in patients with acromegaly. J Clin Invest. 1980;65:43–54.
Bowers CY, Reynolds GA, Hong A, et al. Studies on pituitary cyclic AMP and GH levels and the release of GH in vitro. In: Bhatnager AS, editor. The anterior pituitary gland. New York, NY: Raven Press; 1983. p. 165–76.
Brazeau P, Ling N, Esch F, et al. Somatocrinin (growth hormone releasing factor) in vitro bioactivity, Ca++ involvement, cAMP mediated action and additivity of effect with PGE2. Biochem Biophys Res Commun. 1982;109:588–94.
Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu B, Walker R, editors. Growth hormone II basic and clinical aspects. New York, NY: Springer-Verlag; 1994. p. 203–22.
Bowers CY, Sartor AO, Reynolds GA, et al. On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology. 1991;128:2027–35.
Badger RM, Millard WJ, McCormick GF, et al. The effect of growth hormone (GH) releasing peptide on GH secretion in perifused pituitary cells of adult male rats. Endocrinology. 1984; 115:1432–8.
McCormick GF, Millard WJ, Badger TM, et al. Dose–response characteristics of various peptides with growth hormone releasing activity in the unanesthetized male rat. Endocrinology. 1985;117:97–105.
Sartor O, Bowers CY, Chang D. Parallel studies of HisDTrpAlaTrpDPheLysNH2 and hpGRF in rat pituitary primary cell monolayer culture. Endocrinology. 1985;116:952–7.
Sartor O, Bowers CY, Reynolds GA, et al. Variable determining the GH response of HisDTrpAlaTrpDPheLysNH2 (GHRP-6) in the rat. Endocrinology. 1985;117:1441–7.
Tannenbaum GS, Ling N. The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology. 1984; 115:1952–7.
Plotsky P, Vale W. Patterns of growth hormone-releasing factor and somatostatin into the hypophyseal portal circulation of the rat. Science. 1985;230:461–3.
Brazeau PW, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179:77–9.
Momany FA, Bowers CY. Computer-assisted modeling of Xenobiotic growth hormone secretagogues. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 73–83.
Sethumadhavan K, Veeraragavan K, Bowers CY. Demonstration and characterization of the specific binding of growth hormone-releasing peptide (GHRP) to rat anterior pituitary and hypothalamic membranes. Biochem Biophys Res Commun. 1991;178:31–7.
Bitar KG, Bowers CY, Coy DH. Effects of substance P/Bombesin antagonists on the release of growth hormone by GHRP and GHRH. Biochem Biophys Res Commun. 1991;180:156–61.
Veeraragavan K, Sethumadhavan K, Bowers CY. Growth hormone releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sci. 1992;50:1149–55.
Smith RG, Cheng K, Schoen S, et al. A novel nonpeptidyl growth hormone secretagogue. Science. 1993;260:1640–3.
Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA. 1995;92:7001–5.
Patchett AA, Wyvratt MJ. The design of peptidomimetic growth hormone secretagogues. In: Smith RG, Thorner MO, editors. Human growth hormone. Totowa, NJ: Humana Press, Inc; 2000. p. 45–67.
Codd EE, Shi AYL, Walker RF. Bonding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary sites. Neuropharmacology. 1989;28:1139–44.
Cheng K, Chan WWS, Barreto A, et al. The synergistic effects of HisDTrpAlaTrpDPheLysNH2 on growth hormone (GH) releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary pituitary cell culture. Endocrinology. 1989; 124:2791–8.
Clark RG, Carlsson LMS, Trohnar J, et al. The effects of a growth hormone releasing peptide and growth hormone releasing factor in conscious and anesthetized rats. J Neuroendocrinol. 1989;1:249–55.
Smith RG, Pong SS, Hickey G, et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res. 1996;51:261–86.
Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. Endocrinology. 1994;135:1100–8.
Adams EF, Lei T, Buchfelder M, et al. Protein kinase C-dependent growth hormone releasing peptides stimulate cAMP production by human pituitary somatotrophinomas expressing GSP oncogenes: evidence for cross-talk between transduction pathways. Mol Endocrinol. 1996;10:432–8.
Mau SE, Witt MR, Bjerrum OJ, et al. Growth hormone releasing hexapeptide (GHRP-6) activates the inositol (1,4,5)-triphosphate/diacylglycerol pathway in rat anterior pituitary cells. J Recept Signal Transduct Res. 1995;15:311–23.
Kraicer J, Sims SM. Ionic mechanisms governing the control of growth hormone secretion by somatostatin. In: Bercu B, Walker R, editors. Growth hormone II. New York, NY: Springer Verlag; 1994. p. 17–32.
Chihara K, Kaji H, Hayashi S, et al. Growth hormone releasing hexapeptide: basic research and clinical application. In: Bercu B, Walker R, editors. Growth hormone II. New York, NY: Springer Verlag; 1994. p. 223–30.
Dickson SL, Leng G, Robinson ICAF. Systemic administration of growth hormone releasing peptide activates hypothalamic arcuate neurons. Neuroscience. 1993;53:303–6.
Dickson SL, Luckman SM. Induction of c-fos messenger ribonucleic acid in neuropeptide Y and growth hormone (GH)-releasing factor neurons in the rat arcuate nucleus following systemic injection of the GH secretagogue, GH-releasing peptide-6. Endocrinology. 1997;138:771–7.
Dickson SL, Leng G, Dyball REJ, et al. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology. 1995;61:36–43.
Dickson SL, Doutrelant-Viltart O, Leng G. Growth hormone (GH) deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide (GHRP-6). J Endocrinol. 1995;146:519–26.
Kamegai J, Hasegawa O, Minami S, et al. The growth hormone releasing peptide KP-102 induces c-fos expression in the arcuate nucleus. Mol Brain Res. 1996;39:153–9.
Chan YY, Steiner RA, Clifton DK. Regulation of hypothalamic neuropeptide-Y neurons by growth hormone in the rat. Endocrinology. 1996;137:1319–25.
Howard AD, Scott D, Feighner SD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273:974–7.
Locke W, Kirgis HD, Bowers CY, et al. Effects of intracerebroventricular injection of a growth hormone releasing peptide on feeding behavior and plasma growth hormone levels of rats. Life Sci. 1995;56:1347–52.
Okada K, Ishii S, Minami S, et al. Intracerebroventricular administration of the growth hormone releasing peptide KP-102 increases food intake in free-feeding rats. Endocrinology. 1996;137:5155–8.
Fairhall KM, Mynett A, Thomas GB, et al. Central and peripheral effects of peptide and nonpeptide GH secretagogues on GH release in vivo. In: Bercu B, Walker R, editors. Growth hormone secretagogues. New York, NY: Springer-Verlag; 1996. p. 219–36.
Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31:2235–46.
Bowers CY. GH releasing peptides (GHRPs). In: Kostyo JL, Goodman HM, editors. Handbook of physiology. New York, NY: Oxford University Press; 1999. p. 267–97.
Pong SS, Chaung LYP, Dean DC, et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol. 1996;10:57–61.
Smith RG, Van Der Ploeg LHT, Howard AD, et al. Peptodomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18:621–45.
Van der Ploeg LHT, Howard AD, Smith RG, et al. Molecular cloning and characterization of human, swine, and rat growth hormone secretagogue receptors. In: Bercu BB, Walker RF, editors. Growth hormone secretagogues. New York, NY: Marcel Dekker, Inc; 1998. p. 57–76.
Feighner SD, Howard AD, Prendergast K, et al. Structural requirements for the activation of the human growth hormone secretagogue receptor by peptide and nonpeptide secretagogues. Mol Endocrinol. 1998;12:137–45.
Gnanapavan B, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988–91.
Holst B, Cygankiewicz A, Halkjaer T, et al. High constitutive signaling of the ghrelin receptor: identification of a potent inverse agonist. Mol Endocrinol. 2003;17:2201–10.
Tannenbaum GS, Khoja ZJ, Chang JK, et al. Inhibition of food intake, body weight and GH release via a putative ghrelin O-acyltransferase (GOAT) inhibitor. The Endocrine Society 92nd annual meeting. San Diego, CA. June 19–22, 2010.
Holst B, Schwartz TW. Ghrelin receptor mutations-too little height and too much hunger. J Clin Invest. 2006;116:637–41.
Bowers CY, Laferrere B, Hurley DL, et al. The role of growth hormone secretagogues and ghrelin in feeding and body composition. In: Donohoue PA, editor. Energy metabolism and obesity. Totowa, NJ: Humana Press, Inc; 2008. p. 125–54.
Zigman JM, Jones JE, Lee CE, et al. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol. 2006;494:528–48.
Petersen PS, Woldbye DPD, Madsen AN, et al. In vivo characterization of high basal signaling from the ghrelin receptor. Endocrinology. 2009;150:4920–30.
Korbonits M. Tumours and humors. In: Kleinberg DL, Clemmons DR, editors. Central and peripheral mechanisms in pituitary disease. Bristol: BioScientifica Ltd; 2002. p. 245–62.
Tannenbaum GS, Bowers CY. Interaction of growth hormone secretagogues and growth hormone releasing hormone/somatostatin. Endocrine. 2001;14:21–7.
Tannenbaum GS, Eplelbaum J, Bowers CY. Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in regulation of pulsatile growth hormone secretion. Endocrinology. 2003;144:967–74.
Bowers CY, Reynolds GA, Durham D, et al. Growth hormone releasing peptide stimulates GH release in normal men and acts synergistically with GH releasing hormone. J Clin Endocrinol Metab. 1990;70:975–82.
Ilson BE, Jorkasky DK, Curnow RT, et al. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69:212–4.
Jaffe CA, Ho PJ, De-Mott-Friberg R, et al. Effects of a prolonged growth hormone (GH) releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. 1993;77:1641–7.
Huhn WC, Hartman ML, Pezzoli SS, et al. Twenty-four hour growth hormone (GH) releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specificity attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab. 1993;76:1202–8.
Chapman IM, Hartman ML, Pezzoli SS, et al. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone releasing peptide mimetic, L-692,429, in older adults-a clinical research center study. J Clin Endocrinol Metab. 1996;81:2874–80.
Pandya N, De-Mott-Friberg R, Bowers CY, et al. Growth hormone (GH) releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83:1186–9.
Alster DK, Bowers CY, Jaffe CA, et al. The GH response to GHRP (HisDTrpAlaTrpDPheLysNH2), GHRH and TRH in acromegaly. J Clin Endocrinol Metab. 1993;77:842–5.
Bowers CY, Granda R, Mohan S, et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89:2290–300.
Bowers CY, GHRP: Unatural toward the natural. In: Ghigo E, Boghen M, Casanueva FF, Dieguez C, editors. Growth hormone secretagogues: basic findings and clinical implications. Amsterdam: Elsevier Science; 1999. p. 5–18.
van der Lely AJ, Tschop M, Heiman ML, et al. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev. 2004;25:426–57.
Veldhuis JD, Roemmich JN, Richmond EJ, et al. Somatotropic and gonadotropic axes linkages in infancy, childhood, and the puberty-adult transition. Endocr Rev. 2006;27:101–40.
Korbonits M, Goldstone AP, Gueorguiev M, et al. Ghrelin-the hormone with multiple functions. Front Nueroendocrinol. 2004;25:27–68.
Giustina A, Vedhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19:717–97.
Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.
Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86:1464–9.
Gurd W, Parent G, Eniojukan R, et al. Interrelationship between the novel peptide ghrelin and somatostatin/GHRH in regulation of pulsatile GH secretion. The Endocrine Society 83rd annual meeting. Denver, CO. June 20–23, 2001.
Tannenbaum GS, Epelbaum J, Bowers CY. Ghrelin and the growth hormone neuroendocrine axis. In: Kordon C et al., editors. Brain somatic cross-talk and the central control of metabolism. Berlin/Heidelberg: Springer-Verlag; 2002. p. 65–80.
Hataya Y, Akamizu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab. 2001;86:4552–5.
Veldhuis JD, Reynolds GA, Iranmanesh A, et al. Twenty-four hour continuous ghrelin infusion augments physiological feed-back modes of growth hormones secretion. J Clin Endocrinol Metab. 2008;93:3597–603.
Date Y, Murakami N, Toshinai K, et al. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 2002;123:1120–8.
Veldhuis JD, Bowers CY. Integrating GHS into the ghrelin system. Int J Pept. 2010;Article ID 879503:1–40.
Farhy LS, Veldhuis JD. Deterministic construct of amplifying actions of ghrelin on pulsatile GH secretion. Am J Physiol Regul Integr Comp. 2005;288:R1649–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bowers, C.Y., Reynolds, G.A., Veldhuis, J.D. (2012). Ghrelin: A History of Its Discovery. In: Smith, R., Thorner, M. (eds) Ghrelin in Health and Disease. Contemporary Endocrinology, vol 10. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-903-7_1
Download citation
DOI: https://doi.org/10.1007/978-1-61779-903-7_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61779-902-0
Online ISBN: 978-1-61779-903-7
eBook Packages: MedicineMedicine (R0)